Label (71610 0982 89)
Sacubitril And Valsartan Tablet
Product Images NDC 71610-982
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 71610-982). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena (Aphena)
545 (Sacubitril Valsartan Fig 1)
This is a list showing the Geometric Mean Ratio and 90% Confidence Intervals for various coadministered drugs in relation to a reference. The text mentions drugs such as Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Alorvastatin, and Sildenafil. It shows the change relative to the reference for each drug combination.*
665 (Sacubitril Valsartan Fig 2)
898 (Sacubitril Valsartan Fig 3a)
212 (Sacubitril Valsartan Fig 3b)
The text provides information about the time to occurrence of cardiovascular death in the PARADIGM-HF study comparing Sacubitril and Valsartan with Enalapril. The hazard ratio (HR) with 95% confidence interval is 0.80 (0.71, 0.89). The data includes failure rates for enalapril and sacubitril/valsartan over a period ranging from 360 to 1,260 days since randomization, with the number at risk at each time point listed.*
554 (Sacubitril Valsartan Fig 3c)
This information provides data on the time to the first occurrence of heart failure hospitalizations in the PARADIGM-HF study. The graph shows the failure rate percentage over time for patients treated with Sacubitril & Valsartan compared to Enalapril. The hazard ratio (HR) with 95% confidence interval is reported as 0.79 (0.71, 0.89), indicating a lower risk of heart failure hospitalizations with Sacubitril & Valsartan compared to Enalapril. The time since randomization is depicted in days, ranging from 360 to 1,080 days, with the number of patients at risk decreasing over time in both treatment groups.*
565 (Sacubitril Valsartan Fig 4)
989 (Sacubitril Valsartan Fig 5)
The text includes data related to the time of heart failure hospitalization and cardiovascular death in the PARAGON-HF study. The graph displays the number of participants at risk over time since randomization in days, comparing participants on Sacubitril Valsartan and Valsartan alone. The data shows a decreasing number of participants at risk over time in both groups.*
565 (Sacubitril Valsartan Fig 6)
656 (Sacubitril Valsartan Fig 7)
This text provides information about two clinical trials, PARAGON-HF and PARADIGM-HF, comparing different treatments for heart failure. The trials evaluated the efficacy of sacubitril and valsartan compared to valsartan alone in PARAGON-HF, and to enalapril in PARADIGM-HF. It also mentions the left ventricular ejection fraction measured at screening.*
565 (Sacubitril Valsartan Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
